Atentos a NVAX mañana, anuncio de resultados de fase 2 en conferencia para el Lunes 24
Fecha de conferencia para soltar 3 news
Novavax to Host an RSV F Vaccine Update Conference Call and Webcast on July 24, 2017 at 4:30 PM
- Announce topline data from the Phase 2 Safety and Immunogenicity trial of the RSV F Vaccine in older adults - Provide an Update on the RSV F Vaccine Development Program
GAITHERSBURG, Md., July 17, 2017 /PRNewswire/ -- Novavax, Inc. (Nasdaq:NVAX) today announced it will host a conference Call and webcast on Monday, July 24, 2017, at 4:30 p.m. ET. Novavax anticipates receiving results and announcing topline data from its Phase 2 safety and immunogenicity trial of the RSV F Vaccine in older adults (60 years of age and older). In addition, management will provide an update on its prior Phase 2 and Phase 3 clinical trials in older adults and well as its RSV Phase 3 clinical trial for infants via maternal immunization, known as Prepare™, which continues to experience significant acceleration in enrollment and enhanced momentum heading into its third global season.
Preliminary webcast agenda:
1. Announce topline data from the Phase 2 safety and immunogenicity trial in Older Adults
2. Provide additional findings from prior Phase 2 and Phase 3 clinical trials in Older Adults
3. Update on the Prepare™ trial for Infants via Maternal Immunization